A

Agenus
D

AGEN

3.35000
USD
0.50
(17.54%)
Market Closed
Volume
37,710
EPS
-8
Div Yield
-
P/E
-0
Market Cap
78,587,412
OverviewSignalsIdeasNews
Related Instruments
    C
    CRVS
    -0.31000
    (-3.64%)
    8.21000 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    G
    GNFT
    -1.05000
    (-18.01%)
    4.78000 USD
    O
    ONCY
    -0.02000
    (-2.00%)
    0.98000 USD
    P
    PRTA
    -2.100
    (-13.04%)
    14.000 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Agenus

Sector: Healthcare
Industry: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).